| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 02/04/2026 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 02/04/2026 | P | 138,888 | A | $18 | 138,888 | I | See Footnote(1) | ||
| Common Stock | 02/04/2026 | P | 138,888 | A | $18 | 138,888 | I | See Footnote(2) | ||
| Common Stock | 02/06/2026 | C | 2,387,705 | A | (3)(4) | 2,387,705 | I | See Footnote(5) | ||
| Common Stock | 02/06/2026 | C | 1,151,540 | A | (4)(6)(7) | 1,290,428 | I | See Footnote(1) | ||
| Common Stock | 02/06/2026 | C | 2,155,765 | A | (6)(7)(8)(9)(10) | 2,294,653 | I | See Footnote(2) | ||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Series A Preferred Stock | (3) | 02/06/2026 | C | 10,000,000 | (3) | (3) | Common Stock | 1,340,878 | (3) | 0 | I | See Footnote(5) | |||
| Series A-1 Preferred Stock | (4) | 02/06/2026 | C | 7,807,026 | (4) | (4) | Common Stock | 1,046,827 | (4) | 0 | I | See Footnote(5) | |||
| Series A-1 Preferred Stock | (4) | 02/06/2026 | C | 2,502,252 | (4) | (4) | Common Stock | 335,521 | (4) | 0 | I | See Footnote(1) | |||
| Series B Preferred Stock | (6) | 02/06/2026 | C | 796,380 | (6) | (6) | Common Stock | 106,785 | (6) | 0 | I | See Footnote(1) | |||
| Series B Preferred Stock | (6) | 02/06/2026 | C | 530,920 | (6) | (6) | Common Stock | 71,190 | (6) | 0 | I | See Footnote(2) | |||
| Series B-1 Preferred Stock | (7) | 02/06/2026 | C | 5,289,322 | (7) | (7) | Common Stock | 709,234 | (7) | 0 | I | See Footnote(1) | |||
| Series B-1 Preferred Stock | (7) | 02/06/2026 | C | 3,526,215 | (7) | (7) | Common Stock | 472,822 | (7) | 0 | I | See Footnote(2) | |||
| Series C Preferred Stock | (8) | 02/06/2026 | C | 303,360 | (8) | (8) | Common Stock | 40,677 | (8) | 0 | I | See Footnote(2) | |||
| Series C-1 Preferred Stock | (9) | 02/06/2026 | C | 1,450,614 | (9) | (9) | Common Stock | 194,510 | (9) | 0 | I | See Footnote(2) | |||
| Series D Preferred Stock | (10) | 02/06/2026 | C | 10,266,152 | (10) | (10) | Common Stock | 1,376,566 | (10) | 0 | I | See Footnote(2) | |||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
| Explanation of Responses: |
| 1. These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein. |
| 2. These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| 3. The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. |
| 4. The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. |
| 5. These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein. |
| 6. The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. |
| 7. The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. |
| 8. The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. |
| 9. The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. |
| 10. The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. |
| /s/ Josh Wolfe | 02/06/2026 | |
| /s/ Peter Hebert | 02/06/2026 | |
| Lux Ventures V, L.P., By: Lux Venture Partners V, LLC, its General Partner, By: Peter Hebert, Managing Member /s/ Peter Hebert | 02/06/2026 | |
| Lux Venture Partners V, LLC, By: Peter Hebert, Managing Member /s/ Peter Hebert | 02/06/2026 | |
| Lux Co-Invest Opportunities II, L.P., By: Lux Co-Invest Partners II, LLC, its General Partner, By: Peter Hebert, Managing Member /s/ Peter Hebert | 02/06/2026 | |
| Lux Co-Invest Partners II, LLC, By: Peter Hebert, Managing Member /s/ Peter Hebert | 02/06/2026 | |
| Lux Total Opportunities, L.P., By: Lux Total Opportunities Partners, LLC, its General Partner, By: Peter Hebert, Managing Member /s/ Peter Hebert | 02/06/2026 | |
| Lux Total Opportunities Partners, LLC, By: Peter Hebert, Managing Member /s/ Peter Hebert | 02/06/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||